LIPID-LOWERING EFFICACY OF 20 MG SIMVASTATIN VERSUS 5 MG ROSUVASTATIN IN PATIENTS OF TYPE 2 DIABETES
Keywords:HMG-CoA reductase inhibitor, Lipid-lowering efficacy, Low-density lipoprotein cholesterol, Rosuvastatin, Simvastatin, Type 2 diabetes mellitus (T2DM)
Objective: To compare the efficacy of Rosuvastatin 5mg and Simvastatin 20mg in reducing low-density lipoprotein cholesterol in newly diagnosed patients with type 2 diabetes.
Study Design: Quasi-experimental study.
Place and Duration of Study: Department of General Medicine, Pak Emirates Military Hospital (PEMH), Rawalpindi, from Jul 2017 to Jan 2018.
Methodology: Patients of type 2 diabetes with hypercholesterolemia (mean LDL-C levels >100 mg/dl) were included in the study. In a sample of 100 patients, half of the patients were in the Rosuvastatin 5mg group (group A) while half patients were in the Simvastatin 20mg group (group B). Non-probability consecutive sampling was done. We followed up the patients for 6 weeks. All the laboratory investigations were performed from the laboratory of the same hospital. Investigator himself recorded all the information including name, age, gender, weight, LDL-C levels, Renal function test reports and CK-MB levels in a self-designed, self-administered proforma. Data were analyzed with statistical analysis program SPSS V 23.
Results: Age range in this study was from 35 to 60 years with a mean age of 46.980 ± 6.31 years in group A vs 48.520 ± 5.61 years in group B. Mean LDL-C Levels were 149.460 ± 25.76 mg/dl in group A vs 146.960 ± 22.92 mg/dl in group B. Mean weight was 82.880 ± 9.17 kg in group A vs 88.660 ± 10.33kg in group B. Male gender was dominant in both group (70% and 72%). In group A, efficacy was seen in 40 (80%) patients as compared to 24 (48%) patients in group B (p<0.001).
Conclusion: Rosuvastatin 5mg tablet was more effective than Simvastatin 20mg in reducing low-density lipoprotein cholesterol in newly diagnosed type 2 diabetes patients.